相关实验视频
Updated: Jun 25, 2026

08:50
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
6.9K
确定真正高风险的TP53-突变扩散大B细胞淋巴瘤患者,并探索潜在的生物机制
Kai-Xin Du1,2,3, Yi-Fan Wu1,2,3, Wei Hua1,2,3
1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Cell communication and signaling : CCS
|August 15, 2024
概括
TP53突变影响扩散型大B细胞淋巴瘤 (DLBCL) 的存活率. 一个新的TP53预后指数 (TP53PI) 模型准确地识别高风险TP53突变DLBCL患者,以便更好地分层.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
背景情况:
- TP53突变 (TP53-mut) 与许多癌症的不良结果有关,但它们在扩散性大B细胞淋巴瘤 (DLBCL) 的预后价值仍在争论中.
- 对于TP53-mut DLBCL患者来说,精确的风险分层对于指导治疗决策至关重要.
研究的目的:
- 为TP53-mut DLBCL患者开发一个强大的风险分层模型.
- 确定特定的TP53突变亚型及其对预后和生物通路的影响.
主要方法:
- 分析了来自多个队伍的2637例DLBCL病例.
- 使用机器学习框架构建TP53误解突变风险模型.
- 开发TP53预后指数 (TP53PI) 模型,结合临床数据和突变状态.
主要成果:
- 14.0%的DLBCL患者携带TP53突变,误解突变是最常见的.
- 机器学习模型在预测TP53-mut DLBCL的预后方面表现出高准确度.
- 高风险误解突变与早期进展,免疫和代谢途径失调以及抑制的免疫微环境有关.
结论:
- 该研究成功确定了高风险TP53-mutDLBCL患者.
- TP53PI模型为TP53-mut DLBCL提供了改进的风险分层.
- 了解突变和转录性变化,可以了解疾病进展和免疫逃避.
相关概念视频
Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
The Intrinsic Apoptotic Pathway
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

